Nuclear factor kB as a target for new drug development in myeloid malignancies.
about
Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatmentIs NF-kappaB a good target for cancer therapy? Hopes and pitfallsHyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins.Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies.High Frequency of Inherited Variants in the MEFV Gene in Acute Lymphocytic Leukemia.Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells.Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133aG protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer.NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.MicroRNA-146a and hemopoietic disorders.High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility?Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway.The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.Wedelia chinensis inhibits nasopharyngeal carcinoma CNE-1 cell growth by inducing G2/M arrest in a Chk1-dependent pathway.EGCG targeting efficacy of NF-κB downstream gene products is dictated by the monocytic/macrophagic differentiation status of promyelocytic leukemia cells.Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line.Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia.Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia.High frequency of MEFV gene mutations in patients with myeloid neoplasm.Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode.Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Inhibition of Ubc13-mediated Ubiquitination by GPS2 Regulates Multiple Stages of B Cell Development.Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids.The nuclear factor-kappa B pathway and response to treatment in breast cancer.Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia.Insights on the acetylated NF-κB transcription factor complex with DNA from molecular dynamics simulations
P2860
Q21328704-278AB342-8056-4D8C-B7C0-66361A2EE0AAQ24570128-6DBB4569-A817-4A42-B745-C024C928A38FQ31037798-6972EC7C-45F9-45BF-8CC7-D75FB5910BFAQ33706374-69320412-1D55-42B4-933E-B73A5FAF75A5Q34890498-C8754E53-429D-4E4E-A8AA-553CD0658D32Q35022054-A15E5E38-78F0-4652-AFB5-909FEA84C743Q35163232-C4C099EB-CEC0-4A34-9C00-5E869D9E2DFBQ37109468-D644648F-598D-4E64-A33D-3EE555BD76ADQ37241550-3D5E27DD-47BC-4388-A883-4EFF58CBFBE6Q37293340-DCDD0820-4E5D-4E11-85B9-129B5265BB91Q37790694-7E931BFE-21D0-41EF-9ED9-06AE0EAB159CQ37928982-297EA563-6D8E-4045-AD7E-49847DF757E3Q37997663-36489BE1-E19E-41E8-BC7B-3A126011F693Q38045433-C4EC2C5F-3030-4B72-9CAC-CA121A554A0BQ38505009-64BD09F9-579B-4E27-BC0A-F1BADD848888Q38869842-A406C3AA-F9D2-4548-B4C6-A82D6EDCE1BAQ38951695-61ECF2FD-CDD2-49BA-9B2E-2FBDC4E9AEDFQ39081093-E79D86EC-6148-4632-BDB4-08745B9E4FBDQ39329646-C9BD353D-42AC-4E74-AC93-C789EBD438E4Q39510395-1ED56231-E0F0-4DA9-9BF1-D488C849A70EQ39586108-E0C550C2-4D66-45BF-AB15-18B889BD698AQ39650247-1ED2701D-BCF3-4F2B-9FBF-93F8F8AA7DADQ40297530-BE7A3AFF-1B17-4680-98AB-FE1828AD0B21Q40359750-111CBBB0-0AC8-451B-8513-69439B472618Q41514200-8A438DF8-F511-4E3A-BD88-B4F17E9E3DBEQ41817444-5790F74D-7195-4677-925A-DED9C52FFA06Q41842515-2344A62F-DA68-49F0-B60E-8C89F0486010Q43892008-FADFE4C0-EDDB-446C-8539-6D4623FFD07CQ44707208-EDD783BE-7776-4812-8331-142B356704A3Q45290867-A7C235B3-DB35-4F0D-AE5A-9A1E80C7D71AQ47813995-29CDEB84-2F2B-4D71-941D-625E6D6E8574Q49216080-BD25E3F8-B33C-4F1D-ACE3-3C2226FCCBB3Q57278500-93D0488A-565C-4D01-8E37-88417AE19BCA
P2860
Nuclear factor kB as a target for new drug development in myeloid malignancies.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@ast
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@en
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@nl
type
label
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@ast
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@en
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@nl
prefLabel
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@ast
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@en
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@nl
P50
P356
P1433
P1476
Nuclear factor kB as a target for new drug development in myeloid malignancies.
@en
P2093
Daniela Cilloni
Francesca Messa
P304
P356
10.3324/HAEMATOL.11199
P577
2007-08-01T00:00:00Z